
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Provexis Plc | LSE:PXS | London | Ordinary Share | GB00B0923P27 | ORD 0.1P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
0.575 | 0.65 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Food Preparations, Nec | 802k | -586k | -0.0002 | -30.50 | 14.43M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
13:31:56 | O | 5,355 | 0.5905 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
07/1/2025 | 13:14 | UK RNS | Provexis PLC Grant of Options and Warrants |
31/12/2024 | 13:00 | UK RNS | Provexis PLC Total Voting Rights |
31/12/2024 | 12:28 | ALNC | ![]() |
31/12/2024 | 09:59 | UK RNS | Provexis PLC Half-year Report |
18/12/2024 | 07:00 | UK RNS | Provexis PLC Purchase of Fruitflow® II SD & royalty payment |
25/10/2024 | 15:47 | UK RNS | Provexis PLC Result of AGM |
30/9/2024 | 13:43 | ALNC | ![]() |
30/9/2024 | 07:00 | UK RNS | Provexis PLC Final Results |
Provexis (PXS) Share Charts1 Year Provexis Chart |
|
1 Month Provexis Chart |
Intraday Provexis Chart |
Date | Time | Title | Posts |
---|---|---|---|
15/6/2025 | 20:42 | Provexis: a new beginning | 2,960 |
30/9/2020 | 20:59 | PROVEXIS PLC (Sirco) | 40,155 |
27/4/2013 | 12:43 | Blatherskites, trolls, bashers & duplicitous 'investors' | 631 |
04/9/2012 | 17:24 | PXS herd mentality, medicine, moneymen and manipulation | 3,710 |
20/6/2012 | 01:07 | The Pixies 'Time To Grow Your Tomatoes' Thread | 54 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
12:31:57 | 0.59 | 5,355 | 31.62 | O |
07:00:22 | 0.59 | 7,449 | 43.99 | O |
Top Posts |
---|
Posted at 22/4/2025 14:15 by redprince The silence is deafening but tbf I imagine pxs can't say anything until there is sth to say or at least until By-Health give the green light.The vacuum fuels speculation and whilst I admit to feeling a little uncertain about the next leg I find myself telling me to resist overthinking things. Hopefully some clarity by mid summer. |
Posted at 05/4/2025 07:37 by redprince Sigma...pxs have talked about interest from globals for 15 years...nothing has materialised thus far.Jam tomorrow - director lifestyle co until proven otherwise. |
Posted at 04/4/2025 14:48 by winner31 Ian Ford, the Company's CEO, has been granted 30,000,000 Options which have an exercise price of 0.35 pence. The balance of the Options and all of the Warrants have been granted to the scientific, sales and marketing consultants to the Company and have an exercise price of 0.20 pence. The closing mid-market price of the Ordinary Shares on 6 January 2025, the working day prior to the grants being made, was 0.67 pence. |
Posted at 31/3/2025 19:23 by informer Received this message ................I believe the seller has finished ( c .15 million)not ideal but maybe they were fed up of waiting or needed the money? BYHEALTH continue to register patents ( for use in China only but PXS can use them as illustrations elsewhere) The following is a list of those patents awaiting a shotgun start once the Chinese State Regulator gives approval ,this has obviously taken much longer than anyone thought ,this is due to BYHEALTH's application morphing into a completely new health claim category in China rather than just new products . The State Regulator's men in white coats have replicated all of the science behind Fruitflow that has taken BYHEALTH 8 years to compile. New products have also been launched in Europe. I.P. is a difficult thing to value but we know that worldwide over US $ 40 million has been spent by various companies for their individual Fruitflow products whilst the current mkt.cap of PXS IS C.£11 MM. Anyway once again please may I say keep the faith. |
Posted at 29/1/2025 21:03 by redprince Yes I would not be surprised if there is a HNWI placing to fund the purchase of stock.That is a strong possibility but By-Health launching is a strong probability and when that happens I won't want to buy at the likely share price then hence my decision to buy now.What this really means is a discounted placing accompanied by a share price crash and me feeling miffed at missing a better price!! Let's face it Provexis is the share that never fails to disappoint! |
Posted at 27/1/2025 12:39 by bareknee I hope it works out for you RP. Until the next round of funding is put into place it's pretty much a lottery at the moment.One of my worries about the recent share options being set well below the share price is, if we raise cash by issuing lots of shares, then new and investing investors may well be looking for a discount similar to what the board have given themselves. Gixer - let's hope so, that would probably be the best option for ordinary shareholders. |
Posted at 07/1/2025 18:05 by bareknee I guess if we knew what the performance criteria were, those strike prices, while plainly greedy, wouldn't be too bad.But we don't. If, for example, someone offers 1.0p and all performance criteria are met, then, on the options just issued, Ford stands to gain 30,000,000 * .007 = 210k At a takeover price of 2p that comes to 510k I think he would be likely to be kept on for at least 12 months post any takeover to handover the reins. All in all, even after tax, for someone who'll be 60 soon, that's a nice little earner. I'm not convinced that means his interests, and those of the shareholders, are as aligned as they could be. Having said that, maybe there's an elephant in the room and the low strike prices are signalling Ford and the consultants idea of an exit strategy ( on share price ) is lower than many shareholders are hoping for ? |
Posted at 29/12/2024 16:55 by sigma3333 winnerI hope IF realizes he can’t just do the same cut and paste anymore. e.g. statement around needing more funds has killed the share price Every Aim co needs to raise cash in the future but none chronically harp on about it like PXS. It is clear IF is only interested in the end game, no interest in letting share price rise in line with progress. If he cuts and pastes that one in again, given the recent dilution, then he really doesn’t understand what investors want to see. If there is need to raise more cash to cover a big order, then say so woth specifics, no the blanket statement. The find around the patent gixer kindly shared has changed my mind that he is IF. I firmly believe gixer is in fact our CTO Niamh (my opinion only). siggy |
Posted at 15/8/2024 17:16 by bareknee SmithiePart of what you say is true, but to get there your workings out are a bit ropey. The bit that I'd say you're right about relates to cashflow and PXS having to, or choosing to, issue shares to DSM Firmenich as part payment for a batch of FF. When the results come out in September we'll know, or have a very good idea, as to whether or not we had the cash to pay for that FF and continue operating or not. I suspect we didn't, so it was a way of keeping the wheels turning until we're either cashflow positive, can borrow against future sales or issue more shares in a placing. So there's a big risk there. Where your working out is dodgy relates to the B2B relationship between PXS and DSM. They don't make Fruitflow, they just have some in store which they pretty much can't sell to anyone except PXS, so it's an unusual situation and will likely unravel quite soon ( if it hasn't already ). At that point PXS will have to go to the manufacturer which supplied FF to DSM and negotiate a contract. The issues on cashflow will almost certainly be the same as they are between us and DSM now and, if they can't be resolved, then it's Goodnight Vienna time. Previously our Chief Exec has been able to keep things going via placings,so that's the obvious route to go. What we don't know is if, or more likely when the Chinese company ByHealth, who want to launch over there, will get permission from their regulator. If they get that permission in a timely manner and put decent sized orders in, then borrowing against that gets much easier, as does convincing people to take part in a placing. At that point the hope is that PXS is then profitable, has manageable cashflow and becomes a proper business. What the share price was years ago is immaterial. It was plainly massively overvalued, but that's in the past. |
Posted at 13/8/2024 20:23 by smithie6 ..what's the story here nowadays ?...the owns intel. prop. in some food product which apparently has some health benefits, yes ? but to obtain the product to then supply it to others the co. has to issue a lot of shares to some overseas third party, who apparently make the product, yes ? so, one assumes that PXS itself is virtually bankrupt since it can not pay cash to obtain its own product, to then sell it (at a higher price) All seems "very strange" to me. Surely, normal business practice would be that the mfr makes the stuff, supplies it to PXS (with an invoice asking to be paid) & PXS ships the stuff to clients for cash on delivery or cash in say 10 days. And then PXS pays the product mfr, within 60-90 days. And everyone is happy. And PXS keeps the nett gross profit on its sales. Step & repeat. but no, PXS issues 2% of the shares of PXS to the product mfr. !! seems insane to me. The only logical justification I can see is that PXS is verging on bankruptcy & no one is willing to supply the product without getting paid at delivery, & PXS can not pay, since it pays using shares. It all seems a bit strange imo. ====== Other companies that have relentlessly issued new shares include Craven House. Another disaster. ---- looking at the "all time" chart for PXS, it looks similar perhaps to a hospital monitor display for someone and the last activity on the monitor was in 2010 ! ...& that since then it has just flat lined ! While on the 2 year chart it looks like the sick patient briefly wakes up once per year...only to then slide further downhill ! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions